TY - JOUR
T1 - Serum lidocaine concentrations in children during bronchoscopy with topical anesthesia
AU - Amitai, Y.
AU - Zylber-Katz, E.
AU - Avital, A.
AU - Zangen, D.
AU - Noviski, N.
N1 - Funding Information:
Supported by a grant from the Israeli Ministry of Health.
PY - 1990
Y1 - 1990
N2 - To evaluate the safety of topical lidocaine anesthesia in children undergoing bronchoscopy, we determined SLC in 15 children aged 3 months to 9.5 years during flexible fiberoptic bronchoscopy. A total lidocaine dose of 3.2 to 8.5 (mean±SEM = 5.7±0.5) mg/kg was administered to nose, larynx and bronchial tree over 9 to 45 (mean±SEM = 20±2.7) minutes. No complication occurred during the procedure. Peak SLC were 1-3.5 (mean±SEM = 2.5±0.2) μg/ml. The Vdβ was 1.79±0.19 L/kg, the t1/2β was 109±12 minutes, and the total body clearance 12.2±1.1 ml/min/kg. Peak SLC correlated well with the dose expressed as mg/kg (r=0.59, p<0.025), and even better when related to body surface area (r=0.63, p<0.01). Lidocaine doses up to 8.5 mg/kg proved safe and resulted in therapeutic SLC in our patients. Lidocaine dose up to 7 mg/kg appears to be safe provided that it does not exceed an upper limit of 175 mg/m2 and is gradually administered over a minimum of 15 minutes. Doses of 7-8.5 mg/kg appear to be safe when administered over longer periods.
AB - To evaluate the safety of topical lidocaine anesthesia in children undergoing bronchoscopy, we determined SLC in 15 children aged 3 months to 9.5 years during flexible fiberoptic bronchoscopy. A total lidocaine dose of 3.2 to 8.5 (mean±SEM = 5.7±0.5) mg/kg was administered to nose, larynx and bronchial tree over 9 to 45 (mean±SEM = 20±2.7) minutes. No complication occurred during the procedure. Peak SLC were 1-3.5 (mean±SEM = 2.5±0.2) μg/ml. The Vdβ was 1.79±0.19 L/kg, the t1/2β was 109±12 minutes, and the total body clearance 12.2±1.1 ml/min/kg. Peak SLC correlated well with the dose expressed as mg/kg (r=0.59, p<0.025), and even better when related to body surface area (r=0.63, p<0.01). Lidocaine doses up to 8.5 mg/kg proved safe and resulted in therapeutic SLC in our patients. Lidocaine dose up to 7 mg/kg appears to be safe provided that it does not exceed an upper limit of 175 mg/m2 and is gradually administered over a minimum of 15 minutes. Doses of 7-8.5 mg/kg appear to be safe when administered over longer periods.
UR - http://www.scopus.com/inward/record.url?scp=0025604985&partnerID=8YFLogxK
U2 - 10.1378/chest.98.6.1370
DO - 10.1378/chest.98.6.1370
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 2245677
AN - SCOPUS:0025604985
SN - 0012-3692
VL - 98
SP - 1370
EP - 1373
JO - Chest
JF - Chest
IS - 6
ER -